

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (Currently Amended) An ophthalmic solution comprising 0.001 to 10 weight percent of ~~peptide chosen from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3;~~ and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution not more than 0.2 percent by weight.
2. (Previously Presented) The solution of claim 1, wherein said preservative agent is a cationic polymeric preservative having a concentration between 1 and 100 parts per million.
3. (Original) The solution of claim 1, further comprising a physiologically compatible buffer selected from the group consisting of phosphate, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, Tris, MES, MOPS, PIPES, TAPS, TES, Glycine and Tricine.
4. (Original) The solution of claim 1, further comprising between 0.01% and 5.0% glycerin.
5. (Original) The solution of claim 1 further comprising between 0.01% and 2.0% of decanedioic acid.
6. (Original) The solution of claim 1 further comprising a wetting agent selected from the group consisting of polysorbate surfactants, polyoxyethylene surfactants, phosphonates, saponins and polyethoxylated castor oils.
7. (Original) The solution of claim 1 further comprising a sequestering agent selected

from the group consisting as ethylenediaminetetraacetic acid, phosphonates, citrate, gluconate and tartarate.

8. (Cancelled).

9. (Previously Presented) The solution of claim 1, wherein the concentration of chloride in said solution not more than 0.2 mole percent.

10. (Previously Presented) The solution of claim 1, wherein said solution has a pH between 6.0 and 8.0.

11. (Currently Amended) A method for wetting a contact lens comprising the steps of:
providing a contact lens; and
contacting said contact lens with a solution comprising 0.001 to 10 weight percent of ~~peptide chosen from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3;~~ and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution not more than 0.2 percent by weight.

12. (Previously Presented) The method of claim 11, wherein said preservative agent is a cationic polymeric preservative having a concentration between 1 and 100 parts per million.

13. (Previously Presented) The method of claim 12, wherein said cationic polymeric preservative is polyhexamethylene biguanide.

14. (Previously Presented) The method of claim 11, wherein said solution further comprises a physiologically compatible buffer selected from the group consisting of phosphate, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, Tris, MES, MOPS, PIPES, TAPS, TES, Glycine and Tricine.

15. (Cancelled).

16. (Currently Amended) A method for delivering an ophthalmic solution to the eye comprising the steps of:

providing a bottle comprising a solution comprising 0.001 to 10 weight percent of ~~peptide chosen from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3;~~ and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution not more than 0.2 percent by weight; and

delivering said solution from said bottle to an eye such that the solution comes in direct contact with corneal tissue.

17. (Previously Presented) The method of claim 16, wherein said preservative agent is a cationic polymeric preservative having a concentration between 1 and 100 parts per million.

18. (Previously Presented) The method of claim 17, wherein said cationic polymeric preservative is polyhexamethylene biguanide.

19. (Previously Presented) The method of claim 16, wherein said solution further comprises a physiologically compatible buffer selected from the group consisting of phosphate, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, Tris, MES, MOPS, PIPES, TAPS, TES, Glycine and Tricine.

20. (Cancelled).